The 82% Executive-28% HCP Credibility Gap Persists Deeper Into 2026
97% of pharma digital outreach to HCPs goes unanswered, while 82% of pharma executives believe their efforts are effective, but only 28% of HCPs agree.
Everyone is talking about AI transforming pharma commercial strategy. Very few people are talking about the fact that HCPs still don't believe the outreach is working.
That's the uncomfortable part. And it matters more heading into 2026.
The Gap Isn't New. It's Hardening.
According to Diaceutics, 97% of digital outreach goes unanswered. And while 82% of pharma executives believe their efforts are effective, only 28% of HCPs agree. That's not a small perception gap. That's two organizations describing two different realities.
Deloitte found the same split independently. In its global survey work, "a staggering 82% of life sciences executives are satisfied with their current customer engagement strategies, yet only 28% of HCPs feel that these strategies meet their needs effectively," Deloitte reports. Two firms. Two studies. The same 82-28 split.
That's a pattern.
Where the Disconnect Actually Lives
It would be easy to blame channel fatigue or inbox overload.
That's wrong.
Deloitte's research points somewhere more specific: message quality. "34% of HCPs say that sales reps do not tailor their messages and are ineffective at conveying the scientific narrative," according to Deloitte. That's not a volume problem. That's a judgment problem.
It gets sharper. In a separate Deloitte survey of more than 240 global HCPs and pharma executives, the trust issue goes deeper than tailoring. "Nearly half (47%) of HCPs harbor concerns about the scientific validity of communications from sales representatives and question the authenticity of these resources," Deloitte found.
Not "the messaging felt generic." Concern about scientific validity. Doubt about authenticity. That's a credibility problem wearing an engagement-metrics costume.
Why the Signal Never Gets Read
Here's what should worry commercial leaders more than the headline stat.
Deloitte's broader study, drawing on over 190 HCPs and 50 pharmaceutical executives from the top 25 firms, "revealed a significant gap between pharma's outreach efforts and customer needs." That gap doesn't close because someone adds another channel or another dashboard.
Most organizations can't see the moment where trust breaks down. As Salesforce reports, citing an EPG Health study, "only a quarter (24%) of pharma companies comprehensively analyze HCP engagement data, and less than 20% measure knowledge gain, behavioral change, or impact in practice for most of their HCP education activities."
Most pharma companies aren't measuring whether the interaction changed anything. They're measuring whether it happened.
Those are not the same thing.
Indegene's research describes the structure problem plainly: "Many pharma organizations struggle with fragmented HCP engagement strategies, driven by disparate vendors, platforms, and internal teams each managing a piece of the puzzle. The result? Campaigns that lack cohesion, visibility, and shared accountability."
Fragmented ownership. Fragmented data. Fragmented view of the actual conversation.
No wonder 82% and 28% keep showing up in different studies, years apart. Nobody owns the whole picture.
What 2026 Actually Demands
Executives already sense something is off. Some commentary suggests that biopharma leaders are naming customer engagement and accelerated digital transformation as concerns heading into 2026.
Recognition is a start.
But concern without visibility just produces more of the same. More outreach. More channels. More dashboards counting sends and opens, none of them measuring whether the HCP walked away trusting the conversation.
I don't think the fix is a better campaign. I think it's a different question: not "did we reach them," but "did the interaction hold up." Did the rep notice the hesitation? Did they adjust? Did the follow-up address what the HCP actually raised, or just repeat the deck?
That's not a marketing question. That's a judgment question. And right now, almost nobody is measuring judgment.
Territory coverage. Call volume. Content downloads. All trackable. None of them touch the thing HCPs are actually reacting to, which is whether the person across the table understood the science and adapted the message to what they needed.
The Real Work Ahead
Closing an 82-28 gap doesn't happen through more outreach volume.
It happens by making the quality of the conversation visible, in the same rigorous way pharma already tracks reach and frequency. Treating the moment of interaction, not just the fact of it, as data worth capturing. Not to police reps. To understand where the scientific narrative lands and where it doesn't.
The organizations that figure out how to see that signal, at scale, without turning it into surveillance, are going to close this gap before the next survey cycle.
The ones that don't will keep being surprised by numbers that shouldn't surprise anyone anymore.
What would it actually take for your organization to see the moment credibility is won or lost, instead of just counting that the conversation happened?
Sources
Diaceutics, https://www.diaceutics.com/articles/78af0e4f-d515-49cc-bff4-be3f4eac773c
Salesforce (citing EPG Health study), https://www.salesforce.com/life-sciences/cloud/hcp-pharma/
Indegene, https://www.indegene.com/what-we-think/reports/hcp-engagement-tactics